# Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies

> **NCT07668505** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 10 (estimated)

## Conditions studied

- Myositis

## Interventions

- **DRUG:** maraviroc (Selzentry, Celsentri)

## Key facts

- **NCT ID:** NCT07668505
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668505, "Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*